Maximize your thought leadership

VolitionRx Validates Automated Cancer Test for Pets in Japan, Enhancing Veterinary Diagnostics

By FisherVista

TL;DR

VolitionRx's automated cancer test for pets in Japan provides a market advantage with faster processing for over 1,700 veterinary hospitals.

VolitionRx validated its Nu.Q Vet Cancer Test with Fujifilm Vet Systems for automated processing on the IDS i10 analyzer platform in Japan.

Automated pet cancer testing in Japan enables earlier detection for millions of dogs, improving animal health outcomes and quality of life.

VolitionRx's automated pet cancer test in Japan uses the same platform as human tests, creating cross-species diagnostic synergy.

Found this article helpful?

Share it with your network and spread the knowledge!

VolitionRx Validates Automated Cancer Test for Pets in Japan, Enhancing Veterinary Diagnostics

VolitionRx Limited has completed validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan. This development enables full automation in central laboratories through the IDS i10 automated analyzer platform. The transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows.

More than 1,700 veterinary hospitals in Japan are already registered to use the test, which serves a market of approximately seven million pet dogs. The automated platform aligns with the same system used for Volition's human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy. This validation represents a significant advancement in veterinary diagnostics, potentially improving early detection and monitoring capabilities for canine cancers.

The company's focus on epigenetics and blood-based testing aims to save lives and improve outcomes for both people and animals with life-altering diseases. Volition's research and development activities are centered in Belgium, with additional facilities in the U.S. and London. The company's website at https://volition.com/ provides further information about their diagnostic technologies.

This automation validation addresses growing demand in Japan's veterinary market, where efficient diagnostic tools are increasingly important. The standardized platform across human and veterinary applications may facilitate knowledge transfer and technological advancements in both fields. For more details about the press release, visit https://ibn.fm/k076y.

The implications extend beyond immediate veterinary applications, potentially influencing diagnostic approaches across species. As cancer detection technologies evolve, automated systems like this could become standard in veterinary medicine, improving access to advanced diagnostics for pet owners. The validation in Japan represents an important step in global adoption of epigenetic testing methods.

blockchain registration record for this content
FisherVista

FisherVista

@fishervista